CN121846099A - 治疗造血干细胞移植后的移植物抗宿主病的方法 - Google Patents

治疗造血干细胞移植后的移植物抗宿主病的方法

Info

Publication number
CN121846099A
CN121846099A CN202610271426.3A CN202610271426A CN121846099A CN 121846099 A CN121846099 A CN 121846099A CN 202610271426 A CN202610271426 A CN 202610271426A CN 121846099 A CN121846099 A CN 121846099A
Authority
CN
China
Prior art keywords
days
compound
alkyl
formula
stem cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202610271426.3A
Other languages
English (en)
Chinese (zh)
Inventor
郑翔玲
赵焰平
王红军
仲伟婷
李晶
赵静
刘伟娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tide Pharmaceutical Co Ltd
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of CN121846099A publication Critical patent/CN121846099A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202610271426.3A 2020-07-22 2021-07-21 治疗造血干细胞移植后的移植物抗宿主病的方法 Pending CN121846099A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010713637 2020-07-22
CN2020107136370 2020-07-22
CN202180059344.8A CN116322670A (zh) 2020-07-22 2021-07-21 治疗造血干细胞移植后的移植物抗宿主病的方法
PCT/CN2021/107575 WO2022017412A1 (zh) 2020-07-22 2021-07-21 治疗造血干细胞移植后的移植物抗宿主病的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202180059344.8A Division CN116322670A (zh) 2020-07-22 2021-07-21 治疗造血干细胞移植后的移植物抗宿主病的方法

Publications (1)

Publication Number Publication Date
CN121846099A true CN121846099A (zh) 2026-04-14

Family

ID=79728482

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202610271426.3A Pending CN121846099A (zh) 2020-07-22 2021-07-21 治疗造血干细胞移植后的移植物抗宿主病的方法
CN202180059344.8A Pending CN116322670A (zh) 2020-07-22 2021-07-21 治疗造血干细胞移植后的移植物抗宿主病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180059344.8A Pending CN116322670A (zh) 2020-07-22 2021-07-21 治疗造血干细胞移植后的移植物抗宿主病的方法

Country Status (11)

Country Link
US (1) US20230285393A1 (https=)
EP (1) EP4186508A4 (https=)
JP (1) JP7803924B2 (https=)
KR (1) KR20230043891A (https=)
CN (2) CN121846099A (https=)
AU (1) AU2021313124A1 (https=)
BR (1) BR112023001049A2 (https=)
CA (1) CA3186564A1 (https=)
IL (1) IL299985A (https=)
TW (2) TW202216691A (https=)
WO (1) WO2022017412A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL311447A (en) * 2021-09-18 2024-05-01 Beijing Tide Pharmaceutical Co Ltd A solid form of a Rho-linked protein kinase inhibitor or a solvate thereof, a method of preparation and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202793A1 (en) * 2009-03-09 2012-08-09 Paul Sweetnam Rho kinase inhibitors
CN113620933A (zh) * 2012-10-05 2021-11-09 卡德门企业有限公司 Rho激酶抑制剂
WO2018039539A1 (en) * 2016-08-26 2018-03-01 Lycera Corporation Indazolyl-l,2,4-thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease
CN110582489B (zh) 2017-06-30 2023-10-27 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
WO2019000682A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
US10323023B2 (en) * 2017-06-30 2019-06-18 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
TWI818919B (zh) * 2017-08-15 2023-10-21 美商歐米諾斯公司 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法

Also Published As

Publication number Publication date
JP2023535035A (ja) 2023-08-15
EP4186508A1 (en) 2023-05-31
TW202216691A (zh) 2022-05-01
IL299985A (en) 2023-03-01
KR20230043891A (ko) 2023-03-31
CN116322670A (zh) 2023-06-23
WO2022017412A1 (zh) 2022-01-27
AU2021313124A1 (en) 2023-03-09
TWI868660B (zh) 2025-01-01
EP4186508A4 (en) 2024-10-16
US20230285393A1 (en) 2023-09-14
JP7803924B2 (ja) 2026-01-21
TW202327609A (zh) 2023-07-16
CA3186564A1 (en) 2022-01-27
BR112023001049A2 (pt) 2023-03-07

Similar Documents

Publication Publication Date Title
KR102906316B1 (ko) 지방간 질환 및/또는 지방간염의 치료 방법
CN119868365A (zh) 治疗特发性肺纤维化的方法
CN121846099A (zh) 治疗造血干细胞移植后的移植物抗宿主病的方法
AU2020310296B2 (en) Glucopyranosyl derivatives and their uses
TW202106303A (zh) 二胺基嘧啶類化合物治療子宮內膜異位相關的疼痛的方法
CN114007619B (zh) 二氨基嘧啶类化合物治疗咳嗽的方法
HK40086216A (en) Method for treating graft versus host disease caused by hematopoietic stem cell transplantation
CN109651395B (zh) 一种可靶向降解fkbp12及12.6的化合物及其制备方法和应用
CN120035442A (zh) 治疗尘肺病的方法
HK40058942A (en) Method for treating fatty liver disease and/or steatohepatitis
HK40063173A (en) Method for treating idiopathic pulmonary fibrosis
HK40063168A (en) Method for treating cough by using diaminopyrimidine compound
HK40062124A (en) Method for treating cough by using diaminopyrimidine compound
CN120774829A (zh) 一类氨基酸化合物及其在机体炎症性疾病中的用途
HK40054971B (zh) 治疗脂肪性肝病和/或脂肪性肝炎的方法
HK40064686A (en) Method for treating idiopathic pulmonary fibrosis
HK40063619B (zh) 二氨基嘧啶类化合物治疗子宫内膜异位相关的疼痛的方法

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination